Literature DB >> 26551984

Home Treatment of Deep Venous Thrombosis According to Comorbid Conditions.

Paul D Stein1, Fadi Matta2, Mary J Hughes2.   

Abstract

BACKGROUND: Cautious exploration of the safety of home treatment of deep venous thrombosis has been recommended by many. Our goal was to identify categories of patients with deep venous thrombosis who typically are hospitalized, and categories frequently treated at home.
METHODS: The Nationwide Emergency Department Sample and the Nationwide Inpatient Sample, 2007-2012, were used to determine the number of patients seen in emergency departments throughout the US with deep venous thrombosis and no diagnosis of pulmonary embolism, the proportion of such patients hospitalized according to comorbid conditions and age, the proportion discharged early (≤2 days), and charges for hospitalization and emergency department visits.
RESULTS: From 2007-2012, home treatment was selected for 905,152 of 2,671,452 (33.9%) patients with deep venous thrombosis. Home treatment was more frequent in those with no comorbid conditions than with comorbid conditions, 58.0% compared with 15.5% (P <.0001). Early discharge (≤2 days) was in 23.9% with no comorbid conditions, compared with 12.8% with comorbid conditions. Among patients aged 18-50 years, home treatment was selected in 62.9% with no comorbid conditions, compared with 24.2% with comorbid conditions (P <.0001). Among hospitalized patients with no comorbid conditions, 40.7% were aged 18-50 years. Their charges for hospitalization in 2012 were $494 million.
CONCLUSION: Patients aged 50 years or younger with deep venous thrombosis and no comorbid conditions appear to be a group that can be targeted for more frequent home treatment, which would save millions of dollars.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deep venous thrombosis; Home treatment; Venous thromboembolism

Mesh:

Year:  2015        PMID: 26551984     DOI: 10.1016/j.amjmed.2015.10.022

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

2.  Systematic Review of Real-World Studies Evaluating Characteristics Associated With or Programs Designed to Facilitate Outpatient Management of Deep Vein Thrombosis.

Authors:  Erin R Weeda; Sofia Butt
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389

3.  Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.

Authors:  Jichao Liu; Jinlong Zhao; Yong Yan; Jinping Su
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 4.  Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.

Authors:  Muhammad Ajmal; Jacob Friedman; Qurat Ul Ain Riaz Sipra; Tom Lassar
Journal:  Cardiovasc Ther       Date:  2021-01-08       Impact factor: 3.023

5.  Inpatient Versus Outpatient Acute Venous Thromboembolism Management: Trends and Postacute Healthcare Utilization From 2011 to 2018.

Authors:  Pamela L Lutsey; Rob F Walker; Richard F MacLehose; Faye L Norby; Line H Evensen; Alvaro Alonso; Neil A Zakai
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

6.  Predicting the occurrence of venous thromboembolism: construction and verification of risk warning model.

Authors:  Chen Shen; Binqian Ge; Xiaoqin Liu; Hao Chen; Yi Qin; Hongwu Shen
Journal:  BMC Cardiovasc Disord       Date:  2020-05-27       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.